Gene therapy treatment Luxturna accepted for use in Scotland
Retina UK is delighted that the Scottish Medicines Consortium (SMC) has accepted the gene therapy Luxturna (voretigene neparvovec) for ongoing use by the NHS in Scotland.
Search results
Retina UK is delighted that the Scottish Medicines Consortium (SMC) has accepted the gene therapy Luxturna (voretigene neparvovec) for ongoing use by the NHS in Scotland.
A guide for professionals. Retina UK is a national charity. We offer information and support to people affected by inherited sight loss to enable them to lead better lives today and fund medical research to accelerate the search for treatments for the future. We also support professionals working with them.
Download copies of our Knowledge-base material
The Eye Care Support Pathway is a new framework to ensure patients have timely access to information, advice and support throughout their eye care journey.
During our 50th anniversary year, Retina UK was the focus of a BBC Lifeline Appeal on Sunday 16 November 2025.
Catch up on our BBC Lifeline Appeal from November 2025.
Please find below a research opportunity for people with confirmed stargardt disease.
Sign up to receive regular updates from Retina UK and learn more about the most innovative research and technology news, upcoming events, fundraising and support services available.
Tickle everyone’s taste buds and help raise funds for Retina UK with our Great Bake fundraiser!
When we talk about gene therapy we are usually referring to use of a harmless virus, called a vector, to deliver a normal copy of a defective gene into the cells of the eye.